Biology of Psychiatric Disorders¶
Chapter 462 | Part 13: Neurologic Disorders
KEY CLINICAL POINTS¶
- Psychiatric disorders are heterogeneous CNS diseases with genetic and environmental contributions, characterized by disturbances in emotion, cognition, and socialization.
- Genome-wide association studies (GWAS) and next-gen sequencing have identified hundreds of risk loci for schizophrenia, bipolar disorder, and autism spectrum disorders (ASD).
- Neuroinflammation and cytokine dysregulation (e.g., IL-6, TNF- α ) are implicated in pathogenesis, with potential therapeutic targets in neuroimmune interactions.
- RDoC framework classifies mental illness based on shared behavioral domains (e.g., anhedonia, psychosis) and brain circuits, bridging biology and symptoms.
- Rapid-acting antidepressants like ketamine and emerging psychedelics (e.g., MDMA) target glutamatergic pathways and synaptic plasticity.
1. DEFINITION & OVERVIEW¶
Psychiatric disorders are central nervous system (CNS) diseases characterized by disturbances in emotion, cognition, motivation, and socialization. They are highly heritable (20–90% genetic risk), with heterogeneous etiologies and no definitive biomarkers. Diagnoses rely on DSM-5 criteria, though emerging systems like RDoC aim to integrate biological substrates with behavioral syndromes.
1.1 Core Features¶
Disturbances in emotion, cognition, motivation, and socialization. Severe cases may result in functional decline, with persistent symptoms and comorbidities like depression and suicide risk.
1.2 Diagnostic Challenges¶
DSM-5 classification lacks direct biological correlates. RDoC framework classifies disorders based on shared behavioral abnormalities (e.g., anhedonia, psychosis) and associated brain circuits.
2. EPIDEMIOLOGY¶
Psychiatric disorders are globally prevalent, with early onset and chronic persistence contributing to significant morbidity. Risk factors include genetic predisposition, environmental stressors, and neurodevelopmental vulnerabilities. Neurological conditions like ASD and intellectual disability often co-occur with psychiatric syndromes.
2.1 Incidence/Prevalence¶
ASD: 1 in 54 children (CDC, 2023); schizophrenia: 0.3–0.7% lifetime prevalence; bipolar disorder: 1–2% lifetime prevalence.
2.2 Risk Factors¶
Genetic susceptibility (e.g., CACNA1C, SHANK3), prenatal insults, early life stress, and neuroinflammation. Copy number variations (CNVs) account for ~20–30% of ASD cases.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic, neurobiological, and environmental factors interact to drive psychiatric disorders. Key mechanisms include synaptic dysfunction, neuroinflammation, and dysregulated neurotransmitter systems (e.g., glutamate, dopamine).
Table 462-1: Initial Actions of Drugs of Abuse¶
| DRUG | NEUROTRANSMITTER AFFECTED | DRUG TARGET (ACTION) |
|---|---|---|
| Opioids | Endorphins, enkephalins | m- and d-opioid receptors (agonist) |
| Psychostimulants | Dopamine | Dopamine transporter (antagonist—cocaine; reverse transport—amphetamine, methamphetamine) |
| Nicotine | Acetylcholine | Nicotinic cholinergic receptors (agonist) |
| Ethanol | GABA | GABA receptors (positive allosteric modulator) |
| Glutamate | NMDA glutamate receptors | Antagonist (e.g., phencyclidine) |
| Acetylcholine | Nicotinic cholinergic receptors | Allosteric modulator |
| Serotonin | 5-HT receptor | Positive allosteric modulator |
| Others | Calcium-activated K+ channel | Activator |
| Marijuana | Endocannabinoids | CB receptor (agonist) |
3.1 Genetic Basis¶
GWAS and exome sequencing identify risk loci for schizophrenia (e.g., C4), bipolar disorder (e.g., CACNA1C), and ASD (e.g., SHANK2/3). Polygenic inheritance dominates, with rare de novo mutations contributing to ~10% of cases.
3.2 Neurotransmitter Systems¶
Dopamine dysregulation in reward pathways (VTA-NAc), glutamatergic dysfunction (NMDA receptor), and GABAergic imbalances are central to pathogenesis.
3.3 Neuroinflammation¶
Proinflammatory cytokines (IL-6, TNF- α ) and neuroimmune interactions (astrocytes, microglia) contribute to synaptic pruning deficits and neurodegeneration in schizophrenia and addiction.
4. CLINICAL FEATURES¶
Symptoms vary by disorder but include fatigue, cognitive impairment, mood disturbances, and social withdrawal. Severe cases may present with psychosis, anhedonia, or catatonia. Complications include depression, suicide risk, and functional decline.
4.1 Common Presentations¶
Fatigue, sleep disturbances, cognitive dysfunction, and emotional blunting. Psychotic features (hallucinations, delusions) are prominent in schizophrenia.
4.2 Complications¶
Chronic functional decline, comorbid depression, and increased suicide risk. Neuroinflammation may exacerbate cognitive deficits in schizophrenia.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish psychiatric disorders from medical conditions (e.g., hypothyroidism, Cushing’s syndrome) and other neurologic syndromes (e.g., epilepsy, neurodegenerative diseases). RDoC criteria help identify shared biological pathways across disorders.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes genetic testing (e.g., CNVs, exome sequencing), neuroimaging (fMRI, PET), and biomarkers (e.g., cytokine levels). RDoC framework guides classification based on behavioral domains and neural circuits.
6.1 Laboratory Tests¶
Genome-wide association studies (GWAS), exome sequencing, and cytokine profiling (IL-6, TNF- α ).
6.2 Neuroimaging¶
fMRI identifies altered connectivity in prefrontal cortex and limbic systems; PET detects dopamine receptor abnormalities.
7. MANAGEMENT & TREATMENT¶
Pharmacologic options include SSRIs, SNRIs, antipsychotics, and novel agents (e.g., ketamine, psychedelics). Non-pharmacologic approaches (e.g., CBT, DBS) target neuroplasticity and behavioral patterns.
7.1 Pharmacologic Therapies¶
SSRIs/SNRIs for depression; antipsychotics (e.g., risperidone) for schizophrenia; ketamine for rapid-acting antidepressant effects; psychedelics (e.g., MDMA) for PTSD and depression.
8. PROGNOSIS & COMPLICATIONS¶
Chronic and relapsing course with variable outcomes. Complications include functional decline, comorbid depression, and increased mortality risk. Early intervention and targeted therapies improve prognosis.
8.1 Long-Term Outcomes¶
Schizophrenia: 30–50% functional recovery; ASD: variable outcomes based on genetic and environmental factors.
8.2 Comorbidities¶
Depression, anxiety, and substance use disorders are common. Neuroinflammation may worsen cognitive decline in schizophrenia.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Antidepressants (e.g., SSRIs) may increase birth defects; pediatric: Early intervention for ASD and ADHD; elderly: Polypharmacy risks and cognitive decline.
10. KEY POINTS & CLINICAL PEARLS¶
- Genetic and environmental factors interact in psychiatric disorders. 2. RDoC framework bridges biological mechanisms and clinical symptoms. 3. Neuroinflammation and cytokine dysregulation are therapeutic targets. 4. Rapid-acting agents like ketamine and psychedelics show promise for treatment-resistant depression. 5. Early intervention and personalized therapies improve outcomes.